Physician profile
Alexandra Chebil
NPI 1033290879
$6,163.20
in general payments reported to CMS, 2019-2025
13 companies · $516 in 2025
The $516 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $465 · 2021: $503 · 2022: $1,465 · 2023: $872 · 2024: $890 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,277.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,094.38 | 2019-2025 | Xeomin |
| Allergan, INC. | $1,313.63 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $1,290.46 | 2022-2025 | Miebo, Xiidra, Zylet |
| Alcon Vision LLC | $630.40 | 2019-2025 | Eysuvis, Tryptyr, Rocklatan |
| Kala Pharmaceuticals, INC. | $252.23 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $184.73 | 2020-2024 | Cequa |
| Eyevance Pharmaceuticals LLC | $132.13 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.38 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $52.21 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $51.69 | 2019 | |
| Abbvie INC. | $41.00 | 2023-2024 | Natrelle Saline-Filled Breast Implants |
| Novartis Pharmaceuticals Corporation | $21.56 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Chebil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.